<DOC>
	<DOCNO>NCT01980303</DOCNO>
	<brief_summary>The purpose Phase 1 study characterize pharmacokinetic profile ( body medication ) esketamine give intranasal route ( nose ) healthy adult Japanese Caucasian participant .</brief_summary>
	<brief_title>A Study Assess Pharmacokinetics Intranasally Administered Esketamine Healthy Japanese Caucasian Volunteers</brief_title>
	<detailed_description>This open-label single-center study 2 cohort ( group ) . The study consist screen phase , treatment phase , follow-up visit ( 9 13 day last dose study drug ) . During screen phase , participant evaluate determine meet study eligibility criterion . A target 14 healthy Japanese 14 healthy Caucasian adult participant ( 20 55 year age inclusive ) enrol Cohort 1 Cohort 2 , respectively . The participant cohort self-administer 3 different single-dose regimen intranasal esketamine ( Treatments A , B , C ) 3 treatment period ( ie , 1 treatment per period ) open-label manner ( investigator participant know intervention participant receives ) . The participant randomly ( like toss coin ) assign receive Treatment A Treatment B first two period ( ie , Treatment A Period 1 Treatment B Period 2 , reverse order ) . All participant receive Treatment C Period 3 . The regimen differ number spray achieve total dose total esketamine dose administer . Safety tolerability evaluate throughout study include assessment adverse event , target nasal examination , laboratory test , electrocardiogram , physical examination , pulse oximetery , vital sign .</detailed_description>
	<criteria>Healthy Japanese ( Cohort 1 ) Caucasian ( Cohort 2 ) man woman , 20 55 year age Resided outside Japan 5 year parent maternal paternal grandparent Japanese ethnicity Blood pressure ( participant supine position 5 minute ) 90 145 mmHg systolic , inclusive , high 90 mmHg diastolic A 12lead electrocardiogram consistent normal cardiac conduction function Smokes 10 cigarette , 2 cigar , 2 pipe tobacco per day least 6 month first study drug administration Comfortable selfadministration intranasal medication able follow instruction provide Exclusion criterion : History current clinically significant medical illness include ( limited ) cardiac arrhythmia cardiac disease ; hematologic disease ; coagulation disorder ( include abnormal bleeding blood dyscrasia ) ; hypertension vascular disorder ; significant pulmonary disease , include bronchospastic respiratory disease ; diabetes mellitus ; renal hepatic insufficiency ; thyroid disease ; neurologic psychiatric disease , infection ; kidney/urinary tract disturbance ; sleep apnea , myasthenia gravis , illness investigator considers exclude participant could interfere interpretation study result Clinically significant abnormal value hematology , clinical chemistry , urinalysis screen admission study center Anatomical medical condition may impede delivery absorption study medication Has abnormal deviate nasal septum 1 follow symptom : blockage 1 nostril , nasal congestion ( especially 1sided ) , frequent nosebleed , frequent sinus infection , noisy breathe sleep , time facial pain , headache , postnasal drip Has current diagnosis psychotic disorder , bipolar disorder , mental retardation , borderline personality disorder ; mood disorder postpartum onset , somatoform disorder , fibromyalgia , chronic fatigue syndrome ; generalize anxiety disorder , panic disorder , obsessive compulsive disorder , posttraumatic stress disorder , anorexia nervosa , bulimia nervosa</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>Healthy</keyword>
	<keyword>Japanese</keyword>
	<keyword>Caucasian</keyword>
	<keyword>Anesthetics</keyword>
	<keyword>Intranasal</keyword>
	<keyword>Esketamine</keyword>
	<keyword>Pharmacokinetics</keyword>
</DOC>